RxDoctor Payments Data

Carlos Granja, MD

Nephrology · South Miami, FLNPI 1811179997

Payments from drug & device makers

$3,999in general payments, 2019–2025

Across 146 payments — averaging $27.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$636
  • Amgen$507
  • Otsuka America Pharmaceutical, Inc.$415
  • Fresenius USA Marketing, Inc.$367
  • Calliditas Therapeutics US Inc.$340
  • Bayer$190
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$3,92798%
  • Education$722%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,999 in reported general payments places this provider in the 65th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$256,271
Medicare patients
484
Services billed
1,606

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JynarqueTolvaptan11$217,376
FarxigaDapagliflozin Propanediol146$162,500
JardianceEmpagliflozin98$121,999
VeltassaPatiromer Calcium Sorbitex31$63,634
LokelmaSodium Zirconium Cyclosilicate41$46,217
RetacritEpoetin Alfa-Epbx23$31,282
VascepaIcosapent Ethyl42$17,135
Bumetanide420$12,096
SpsSodium Polystyrene Sulfon/Sorb19$8,753
Cinacalcet Hcl32$5,881
Valsartan185$3,796
Chlorthalidone149$3,120
Nifedipine ErNifedipine79$2,189
Doxazosin Mesylate111$1,989
Calcitriol84$1,247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Jynarque$415$217,37611 claims
AstraZenecaFarxiga, Lokelma$636$208,717187 claims
Boehringer IngelheimJardiance$154$121,99998 claims
ANI Pharmaceuticals, Inc.Valsartan$34$3,796185 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 756 nephrology providers in Florida.

Other nephrology in South Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →